This study was undertaken to evaluate the long-term safety and effectiveness of fenfluramine in patients with Lennox-Gastaut syndrome (LGS).
Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study / Kelly G Knupp , Ingrid E Scheffer , Berten Ceulemans , Joseph Sullivan , Katherine C Nickels , Lieven Lagae , Renzo Guerrini, Sameer M Zuberi , Rima Nabbout , Kate Riney , Anupam Agarwal, Michael Lock , David Dai , Gail M Farfel , Bradley S Galer , Arnold R Gammaitoni , Shikha Polega , Ronald Davis, Antonio Gil-Nagel. - In: EPILEPSIA. - ISSN 0013-9580. - ELETTRONICO. - (2023), pp. 0-0. [10.1111/epi.17431]
Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study
Renzo Guerrini;
2023
Abstract
This study was undertaken to evaluate the long-term safety and effectiveness of fenfluramine in patients with Lennox-Gastaut syndrome (LGS).
| File | Dimensione | Formato | |
|---|---|---|---|
|
Epilepsia - 2022 - Knupp - Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Creative commons
Dimensione
2.58 MB
Formato
Adobe PDF
|
2.58 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
